Keefe, R., Woods, S., Cannon, T., Ruhrmann, S., Mathalon, D., McGuire, P., … Sand, M. (2017). M15. Early Intervention in Attenuated Psychosis Syndrome: A Phase II Study Evaluating Efficacy, Safety, and Tolerability of Oral BI 409306. In Schizophrenia Bulletin (Vol. 43, pp. S216–S217). Oxford University Press (OUP). https://doi.org/10.1093/schbul/sbx022.014

Keefe, Richard, Scott Woods, Tyrone Cannon, Stephan Ruhrmann, Daniel Mathalon, Philip McGuire, Gwenaëlle Fillon, Holger Rosenbrock, and Michael Sand. “M15. Early Intervention in Attenuated Psychosis Syndrome: A Phase II Study Evaluating Efficacy, Safety, and Tolerability of Oral BI 409306.” In Schizophrenia Bulletin, 43:S216–17. Oxford University Press (OUP), 2017. https://doi.org/10.1093/schbul/sbx022.014.

Keefe R, Woods S, Cannon T, Ruhrmann S, Mathalon D, McGuire P, et al. M15. Early Intervention in Attenuated Psychosis Syndrome: A Phase II Study Evaluating Efficacy, Safety, and Tolerability of Oral BI 409306. In: Schizophrenia Bulletin. Oxford University Press (OUP); 2017. p. S216–7.

Keefe, Richard, et al. “M15. Early Intervention in Attenuated Psychosis Syndrome: A Phase II Study Evaluating Efficacy, Safety, and Tolerability of Oral BI 409306.” Schizophrenia Bulletin, vol. 43, no. suppl_1, Oxford University Press (OUP), 2017, pp. S216–17. Crossref, doi:10.1093/schbul/sbx022.014.

Keefe R, Woods S, Cannon T, Ruhrmann S, Mathalon D, McGuire P, Fillon G, Rosenbrock H, Sand M. M15. Early Intervention in Attenuated Psychosis Syndrome: A Phase II Study Evaluating Efficacy, Safety, and Tolerability of Oral BI 409306. Schizophrenia Bulletin. Oxford University Press (OUP); 2017. p. S216–S217.